As an example, HER2/neu peptide, which has addressed the pathological relevance to breast cancer, has been developed as the breast cancer vaccine and is currently assessed under ongoing clinical trials with the immunoadjuvant, granulocyte–macrophage colony-stimulating factor (GM-CSF) (Abbaspour and Akbari 2022). Here, ERBB2 is linked to breast carcinoma.